Science

Pipeline Overview

BerGenBio is focused on developing its leading selective AXL inhibitor bemcentinib as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory illnesses

Happy couple

Bemcentinib Indication Pipeline

Preclinical
Phase 1
Phase 2
Registrational Study

Severe
respiratory
infections

Targeted IndicationHospitalized COVID-19
Hospitalized COVID-19
Phase 2
Targeted IndicationOther Viral Pathogens
Other Viral Pathogens
Phase 1

Oncology

Targeted Indication2L Acute Myeloid Leukemia
2L Acute Myeloid Leukemia
Phase 2
Targeted Indication2L Non-Small Cell Lung Cancer
2L Non-Small Cell Lung Cancer
Phase 2
Targeted Indication2L Adenocarcinoma Lung Cancer (w/ pacritinib*)
2L Adenocarcinoma Lung Cancer (w/ pacritinib*)
Phase 2

*Marketed by Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company. Pacritinib (marketed as VONJO®) is a JAK2 inhibitor indicated for treatment of myelofibrosis, a bone marrow disorder, and works by blocking certain growth factors and cytokines.